Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the international committee on chelation deferipronedeferoxamine combination protocol

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 312-322

  Kolnagou, Anita ^a   Yazman, Dilek ^a   Economides, Charalambos ^a   Eracleous, Eleni ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Deferiprone (L1); Deferoxamine (DFO); Ferrikinetics; Magnetic resonance imaging (MRI) T2 and T2 *diagnosis; Serum ferritin; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; CHILD; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HEART; HUMAN; IRON KINETICS; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHOOL CHILD; THALASSEMIA MAJOR; TISSUE LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHELATION THERAPY; CHILD; DEFEROXAMINE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PYRIDONES; SIDEROPHORES; THALASSEMIA; YOUNG ADULT;

EID: 70350664643     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903213231     Document Type: Conference Paper

References (14)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;ii(8653):27-29.
2. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll, and their combinations. Curr Med Chem. 2005;12(23):2663-2681.
3. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-331.
4. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 Relaxation time study of iron overload in b-thalassemia. MAGMA. 1998;6(1):7-12.
5. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in b-thalassaemia. Lancet. 2002;360(9332):516-520.
6. Wood JC, Ghugre N. Magnetic Resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin. 2008;32(1-2):85-96.
7. Kolnagou A, Eracleous E, Economides Ch, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting excess cardiac iron loading and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin. 2006;30(2):219-227.
8. Anderson LJ, Westwood MA, Prescott E, et al. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115(1-2):106-108.
9. Kolnagou A, Fessas Ch, Papatryphonas A, et al. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol. 2004;127(3):360-361.
10. Gotsis ED. The uses and differences of R2 and R2* in the determination of iron overload in iron loaded thalassemia patients. Hemoglobin. 2008;32(1-2):75-83.
11. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30(2):239-249.
12. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41-47.
13. Positano V, Pepe A, Santarelli MF, et al. Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. NMR Biomed. 2009;(Epub ahead of print).
14. Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003;361(9352):184.